Articles
Alzheon Chief Medical Officer, Susan Abushakra, MD, gives a podium presentation at the AAIC
Alzheon’s CMO Dr Susan Abushakra, delivered this morning an excellent presentation of the 6-months Phase 2 Biomarker study that showed strong P-tau reduction in plasma, improvement on cognition and favorable safety profile with no evidence of brain edema.
ALZ-801 (Balitramiprosate) is in Phase 3 and currently recruiting https://apolloe4.
ALZ-801 (https://alzheon.com/)has the potential to become the first oral disease modifying therapy for Alzheimer.
Looking forward to the conversation and hearing from more brilliant speakers.
